Merus (MRUS) Climbs 0.21% on $270M Volume Ranks 405th in Daily Trading Activity

Merus (MRUS) closed on October 9, 2025, , , ranking 405th in market activity for the day. The stock's modest gain came amid selective sector movements and limited broader market catalysts.

Recent developments highlighted Merus' position in its therapeutic pipeline advancements. The biotech firm announced preliminary data from its Phase II trials for a next-generation candidate, demonstrating improved pharmacokinetic profiles compared to its prior platform. While no definitive efficacy metrics were disclosed, the update reinforced investor confidence in its R&D execution capabilities.

Analysts noted the stock's muted performance relative to peers, attributing it to cautious positioning ahead of Q3 earnings reports. Merus' capital allocation strategy, including its recent partnership with a for co-development rights, remains a focal point for technical analysis. Short-term momentum indicators suggest consolidation patterns, .

To set this up properly I need to pin down a couple of details: 1. Market universe – are we looking at all U.S. listed common stocks (NYSE + NASDAQ + Arca), or a different exchange set? 2. Weighting – should the 500 names be held equally-weighted each day, or weighted by something else (e.g., proportional to dollar volume)? 3. Benchmark – do you want the results compared with any particular index (e.g., SPY) for context? Once I have those points I can pull the data, build the daily re-balanced portfolio, and run the back-test from 2022-01-01 to today.